Dysregulation of DNA methyltransferase (DNMT)1 expression is associated with cellular transformation, and inhibition of DNMT1 exerts antitumorigenic effects. Here, we report that DNMT1 abnormally expressed in HeLa cells is downregulated by a histone deacetylase (HDAC) inhibitor apicidin, which is correlated with induction of repressive histone modifications on the promoter site. Apicidin selectively represses the expression of DNMT1 among DNMTs in HeLa cells, independent of cell cycle arrest at G 0 /G 1 . Furthermore, apicidin causes a significant reduction in the recruitment of RNA polymerase II into the promoter. Chromatin immunoprecipitation analysis shows that even though apicidin causes global hyperacetylation of histone H3 and H4, localized deacetylation of histone H3 and H4 occurs at the E2F binding site, which is accompanied by the recruitment of pRB and the replacement of P/CAF with HDAC1 into the sites. In addition, K4-trimethylated H3 on nucleosomes associated with the transcriptional start site is depleted following apicidin treatment, whereas repressive markers, K9-and K27-trimethylation of H3 are enriched on the site. The downregulation of DNMT1 expression seems to require de novo protein synthesis, because the apicidin effect is antagonized by cycloheximide treatment. Moreover, knock down of DNMT1 with siRNA induces the apoptosis of HeLa cells, indicating that downregulation of DNMT1 might be a good strategy for therapeutics of human cervix cancer. Collectively, our findings will provide a mechanistic rationale for the use of HDAC inhibitors in cancer therapeutics.
Introduction
It is well known that histone deacetylase (HDAC) inhibitors alter expression of many tumor-associated proteins and exhibit clinical activity against a variety of human malignancies; this antitumor activity may be characterized as either inducing cytostasis (cell cycle arrest), differentiation or apoptosis. It has also been generally accepted that more actively transcribed chromatin regions are associated with histone hyperacetylation and recruitment of histone acetyltransferases (HATs), and histone deacetylation associated with recruitment of HDACs often restores these genomically active regions to a more repressed and condensed chromatin state (Beaulieu et al., 2002) . Thus, an attractive paradigm for the antitumor action of HDAC inhibitors has been the induction of histone acetylation producing transcriptional activation of critical genes needed for tumor growth arrest (Cress and Seto, 2000) . Aside from the upregulation of epigenetically silenced tumor suppressor proteins or induction of caspases and other proapoptotic proteins by HDAC inhibitors (Juan et al., 2000; Kwon et al., 2002; Fuino et al., 2003; Mitsiades et al., 2004) , emerging data are showing HDAC inhibitor-induced repression of critical transforming growth factor mechanisms, such as those involving oncogenic tyrosine kinases like bcr/abl, ErbB2 and DNA methyltransferase (DNMT) 3B Nimmanapalli et al., 2003) . Indeed, several studies using DNA microarray analysis have now revealed that fewer than 10% of expressed genes in a given malignant cell population are affected by an antitumor dose of an HDAC inhibitor, with a near equal number of transcriptionally active genes being repressed as those being stimulated (Drummond et al., 2005) . However, the HDAC-dependent mechanisms accounting for the observed and rather selective modulation of gene expression, as well as specific patterns of antitumor activity, remain poorly understood.
Epigenetic modifications such as DNA methylation, histone acetylation and histone methylation regulate chromatin structure and function. Generally, DNA methylation on cytosine in CpG dinucleotides in the regulatory regions of genes is associated with gene silencing either by directly inhibiting the interaction of transcription factors with their regulatory sequences (Watt and Molloy, 1988) or by attracting methylated DNA-binding proteins such as MeCP2, which in turn recruits HDACs and histone methyltransferases, resulting in an inactive chromatin structure (Boyes and Bird, 1991; Nan et al., 1998) . DNA methylation in mammalian cells is regulated by a family of highly related DNMT, DNMT1, DNMT3A and DNMT3B, which catalyse the transfer of methyl groups from S-adenosyl-L-methionine to the 5 0 position of cytosine bases in the dinucleotide sequence CpG (Bestor et al., 1988; Okano et al., 1998) . In vitro, DNMT1 prefers hemimethylated DNA over non-methylated DNA as substrate and is therefore responsible for propagation and maintenance of established methylation patterns during embryonal development and cell division. DNMT1 expression is properly cell cycle-regulated in normal cells to establish their function (Leonhardt et al., 1992) . DNMT1 is recruited to replication foci through protein interactions involving the DNMT1-associated protein-binding region (Rountree et al., 2000) , the proliferating cell nuclear antigenbinding region (Chuang et al., 1997) and the replication foci targeting sequence. On the other hand, de novo methylation of DNA is believed to be performed by DNMT3A and DNMT3B (Okano et al., 1998) . However, these classifications are oversimplified as DNMT1 is also known to possess de novo methylation activity (Hermann et al., 2004) and is the most abundant methyltransferase in somatic cells (Robertson et al., 1999) .
Although genetic alterations such as deletion, amplification and translocation have been well demonstrated to play a critical role in cancer initiation and progression, epigenetic modifications of DNA are also associated with these processes through the regulation of gene transcription (Eden and Cedar, 1994; Pradhan et al., 1999) . Aberrant CpG methylation has been observed in several tumors (Baylin and Herman, 2000) . Some CpG islands are hypermethylated in tumor cells (Baylin et al., 1998; Yan et al., 2003) , suggesting that a fundamental disruption of methylation control has occurred. This aberrant hypermethylation can act in a manner analogous to deletion or mutation of growth inhibitory genes, thereby producing a selective growth advantage (Wu et al., 1993; Jones and Baylin, 2002; Gupta et al., 2003) . DNMT1 has been shown to act as an oncogene in cultured fibroblasts (Wu et al., 1993) . Furthermore, NIH 3T3 cells transformed by DNMT1 show enhanced DNA methylation; these cells form tumors when transplanted into nude mice (Wu et al., 1993) . Conditional expression of c-fos upregulates expression of Dnmt1, resulting in morphological transformation of rat fibroblasts (Bakin and Curran, 1999 ). Interestingly, a low level of DNMT1 overexpression leads to cell transformation, whereas a high level is toxic (Wu et al., 1993) . In addition, subcutaneous injection of the DNMT1 inhibitor 5-aza-2 0 -deoxycytidine decreases polyp number in Min mice that are heterozygous for the multiple intestinal neoplasia mutation of the adenomatosis polyposis coli gene (Laird et al., 1995) . The mechanisms through which DNMT1 causes cellular transformation and through which inhibition of DNMT1 reverses cellular transformation are unknown (Baylin et al., 2001) . The most obvious mechanism is that aberrant expression of DNMT1 causes methylation and silencing of tumor suppressor genes (Beaulieu et al., 2002; Robert et al., 2003; McCabe et al., 2006a) . This hypothesis is supported by numerous documentations of methylated tumor suppressor genes in tumors (LopezSerra et al., 2006; Marsit et al., 2006) . In accordance with this hypothesis, knock down of DNMT1 by either antisense or siRNA results in demethylation and activation of tumor suppressor genes, such as p16 and p21 (Fournel et al., 1999; Milutinovic et al., 2000; Robert et al., 2003) . These data suggest that increased DNMT levels and activity affect the methylation status of genes critical to tumor formation. Thus, DNMT1 expression must be tightly regulated during normal cell growth.
In this study, we investigate the selective modulation of DNMT1 gene expression in HeLa cells by an HDAC inhibitor, apicidin, which inhibits proliferation of various tumor cells with a broad spectrum of antiproliferative activity against various cancer cell lines (Han et al., 2000) . In particular, we focus on the transcriptional regulation of DNMT1 by apicidin and demonstrate that apicidin downregulation is attributed to the inhibition of transcription initiation, independent of cell cycle arrest at G 0 /G 1 , and the effect is mediated through induction of repressive histone modifications in the promoter region via recruitment of the corepressor complex.
Results

DNMT1 expression in
HeLa cells is dysregulated during cell cycle and apicidin decreases DNMT1 mRNA and protein levels in various cancer cell lines DNMT1 expression has been reported to be regulated in cell cycle-dependent manner (Szyf et al., 1991; Leonhardt et al., 1992) . To examine if DNMT1 is normally S phase regulated in the human cervix cancer cell line HeLa, we first analysed changes in DNMT1 expression during the cell cycle. HeLa cells synchronized by serum starvation were stimulated with serum; fractions of G 0 / G 1 , S and G 2 /M phase were determined by propidium iodide staining of DNA content and flow cytometry. While HeLa cells progress through the cell cycle as evidenced by the distribution of cell population (Figure 1b) , there is no change in DNMT1 protein level during cell cycle, indicating dysregulation of DNMT expression in HeLa cells (Figure 1a ). Gene silencing of DNMT, which can act as an oncogene, has been proposed to be a good strategy for cancer therapeutics (Lee et al., 2005; Gore et al., 2006) . Therefore, we then examined the potential of HDAC inhibitor apicidin to suppress the expression of DNMT1, DNMT3A and DNMT3B in HeLa cells. Apicidin treatment markedly reduces the level of DNMT1 mRNA and protein in a dose-dependent manner (Figures 1c and 2a) , while apicidin has little effect on expression of DNMT3A and DNMT3B (Figure 1c) . In contrast, the expression of cyclindependent kinase inhibitor p21 WAF1/Cip1 increases following apicidin treatment (Figures 1c and 2a) , consistent with a previous report (Han et al., 2000) .
To examine whether the observed apicidin effect is specific to HeLa cells, we expanded the investigation to include changes of apicidin-mediated DNMT1 expression in other cancer cell lines. Following treatment with apicidin for 24 h, DNMT1 protein levels dramatically decrease in NCCIT, human embryonic carcinoma cells, MCF-7, human breast cancer cells and HCC1954, human ductal carcinoma cells (Figure 2b ). These results indicate that apicidin downregulates DNMT1 expression in various types of cancer cells.
Apicidin-induced downregulation of DNMT1 is independent of cell cycle arrest at G 0 /G 1 Apicidin has been demonstrated to induce cell cycle arrest at G 0 /G 1 in HeLa cells (Han et al., 2000) . These findings led to the assumption that apicidin-induced downregulation of DNMT1 might be due to cell cycle arrest at G 0 /G 1 phase. To examine the possibility, HeLa cells were arrested in G 0 /G 1 , and then changes in the levels of DNMT1 mRNA and protein were determined by reverse transcription (RT)-PCR and western blot analysis following treatment with apicidin or mevinolin, a pharmacological inhibitor of cell cycle at G 0 /G 1 for 24 h (Rao et al., 1998) . As expected, both apicidin and mevinolin treatments lead to the induction of p21 WAF1/Cip1 (Figure 3a ) and the G 1 arrest, as evidenced by an increase in the number of cells at G 0 /G 1 up to 87 and 85% from 67%, respectively ( Figure 3b ). Apicidin significantly reduces the levels of DNMT1 mRNA and protein, but mevinolin does not alter those expressions ( Figure 3a ). This finding indicates that apicidin downregulation of DNMT1 expression might be independent of apicidin-induced G 1 arrest or the induction of p21 WAF1/Cip1 expression.
Downregulation of DNMT1 expression by apicidin occurs at the transcriptional level
To address the possible mechanisms by which apicidin downregulates DNMT1 expression, we examined the effect of apicidin on the transcription of DNMT1 by determining the recruitment of RNA polymerase II (Pol II) into the transcription initiation site (B region) and coding region (C region) ( Figure 4a ; Bigey et al., 2000) . Chromatin immunoprecipitation (ChIP) analysis using anti-Pol II antibody shows that apicidin significantly but not completely suppresses the transcriptional initiation, resulting in a decrease in the transcriptional elongation as evidenced by the 60 and 65% decrease in recruitment of Pol II into the transcription initiation site and coding region, respectively ( Figure 4b ). However, apicidin does not affect the recruitment of Pol II into the transcription initiation and coding region of glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Figure 4c ). These results suggest that apicidin downregulates DNMT1 expression via inhibition of transcription, and that a mechanism other than transcriptional inhibition might also be partly associated with the downregulation of DNMT1 expression.
Apicidin induces repressive histone modifications and recruitment of pRB and HDAC1 to the E2F binding site Histone modifications such as acetylation and methylation play an important role in regulation of gene expression through altering chromatin structure (Li et al., 2007) . To examine whether downregulation of DNMT1 expression by apicidin is associated with alteration of histone modifications on the promoter region, we performed ChIP analysis. Apicidin treatment leads to the locally significant hypoacetylation of histone H3 and H4 on the transcriptional initiation site (B region) (Figure 5a ), although the global acetylation of histone H3 and H4 increases as expected (Figure 5b ). Recent progress has highlighted the importance of three histone lysine methylations in epigenetics. Whereas methylation of histone 3 lysine 9 (H3-K9) and H3-K27 direct gene silencing, methylation of H3-K4 is associated with gene expression (Kouzarides, 2007) . K4-trimethylated H3 on nucleosomes associated with the transcription initiation site is depleted following apicidin treatment, whereas repressive markers K9-trimethylation and K27-trimethylation of H3 are enriched on the site (Figure 5a ). However, apicidin treatment dose not significantly alter the histone modifications upstream of the promoter region (A region).
It has been demonstrated that a conserved E2F consensus-binding site is located in proximity to the transcription initiation points of murine and human DNMT1, and that the DNMT1 promoter is regulated by the pRB/E2F pathway (McCabe et al., 2005) . Thus, we examined whether apicidin-induced downregulation of transcriptional initiation is mediated through alteration of this pathway. First, we tested the binding of E2F and pRB to the conserved E2F binding site in vivo in the absence of apicidin. ChIP analysis reveals that in the absence of apicidin, E2F is constitutively bound to the E2F binding site, while pRB is not able to bind to the site (Figure 5c ). However, apicidin treatment causes the marked recruitment of pRB into the site. Furthermore, pRB recruitment is accompanied by an increase in the recruitment of HDAC1 into the site (Figure 5c ). In contrast, P/CAF, an HAT, is dissociated from the site upon apicidin treatment (Figure 5c ). Taken together, the results indicate that the transcriptional repression of DNMT1 by apicidin might be attributed to repressive histone modifications through the formation of corepressor complexes on the E2F binding site.
De novo protein synthesis is required for the transcriptional repression of DNMT1 by apicidin We next investigated whether apicidin-induced downregulation of DNMT1 expression is mediated by de novo protein synthesis. As shown in Figure 6a , pretreatment of HeLa cells with the protein synthesis inhibitor cycloheximide (CHX) recovers the decrease of DNMT1 mRNA level induced by apicidin, indicating the requirement of protein synthesis for the transcriptional repression of DNMT1. Consistent with the results, CHX treatment abrogates the recruitment of pRB and HDAC1 to the E2F binding site by apicidin, leading to hyperacetylation of histone H3 (Figure 6b) . Collectively, the results suggest that apicidin action on the transcription of DNMT1 requires de novo protein synthesis.
Knock down of DNMT1 induces expression of p21
WAF1/Cip1 and apoptosis Recently, it has been shown that an inverse correlation exists between p21 WAF1/Cip1 and DNMT1 protein levels in SV40-transformed and -nontransformed cells (Chuang , which can be further increased by apicidin treatment (Figure 7a ). These results indicate that the upregulation of p21 WAF1/Cip1 by apicidin might be partially mediated through downregulation of DNMT1.
We then examined whether DNMT1 knockdown affects the biological process of HeLa cells. To do this, we determined the effect of DNMT1 knockdown on apoptosis of HeLa cells by analysing Annexin V staining using flow cytometry. As shown in Figure 7b , DNMT1 knockdown leads to significant increase in the number of Annexin V-positive cells (26.19%), compared to control siRNA (5.96%). To gain insights into the mechanism by which the inhibition of DNMT1 expression induces apoptosis, we investigated the effect of siRNA against DNMT1 on cleavages of caspase-3 and poly-(adenosine diphosphate-ribose) polymerase (PARP). DNMT1 knockdown induces the activation of capase-3, resulting in subsequent cleavage of PARP (Figure 7c ). However, treatment of HeLa cells with apicidin does not cause cleavages of neither caspase-3 nor PARP (Figure 7c) , consistent with our previous observation showing that apicidin does not induce apoptosis of HeLa cells (Kim et al., 2006) . The results suggest that DNMT1 might be a good target for inducing apoptosis of HeLa cells.
Discussion
DNMT1 is crucial for maintaining normal DNA methylation patterning during embryonal development and cell division (Li et al., 1992; Walsh and Bestor, 1999; Reik et al., 2001) . Recently, several studies have demonstrated that dysregulation of DNMT1 expression plays a critical role in cellular transformation (McCabe et al., 2006a) . Moreover, inhibition of DNMT1 in various cancer cells using antisense, RNA interference and pharmacological inhibitors induces reexpression of various methylation-silenced tumor suppressor genes, leading to a decrease in transformation and proliferation. In this study, we describe a novel molecular mechanism by which apicidin downregulates DNMT1 expression. Apicidin induces the dissociation of activator, P/CAF and the recruitment of corepressors, pRB and HDAC1, into the promoter region containing the E2F binding site, which is accompanied by repressive histone modifications on the site, including hypoacetylation of histone H3 and H4, hypomethylation of histone H3-K4 and hypermethylation of H3-K9 and H3-K27 ( Figure 5 ). In parallel, the recruitment of Pol II into the promoter region and coding region is suppressed (Figure 4 ). These findings strongly suggest that repressive histone modifications associated with nucleosomes of the DNMT1 promoter by apicidin might be responsible for the repression of DNMT1 abnormally expressed in HeLa cells.
Numerous HDAC inhibitor studies have focused on mechanisms of gene activation and demonstrated that histone hyperacetylation induced by inhibition of HDAC activity is associated with gene transactivation (Marks et al., 2001) . For example, suberoylanilide hydroxamic acid (SAHA) caused dissociation of HDAC1 from the p21 promoter without detectable change in the HDAC1 protein (Gui et al., 2004) . The loss of HDAC1 on the promoter is correlated with the accumulation of acetylated H3 and H4, which may play a role in SAHA-induced increases in acetylation of the histones. In contrast, emerging evidence has shown that HDAC inhibitors can also induce localized histone hypoacetylation in the promoter region, leading to the repression of gene expression, although the molecular mechanism remains to be established (Ferguson et al., 2003) . Recently, the HDAC inhibitor trichostatin A (TSA) has been shown to downregulate de novo DNMT3B expression by decreasing DNMT3B mRNA stability (Xiong et al., 2005) . A previous report also revealed that TSA treatment inhibits the mRNA synthesis of Her-2/neu as detected by a genomically integrated Her-2/neu promoter cell screen (Scott et al., 2002) . While exposure to TSA had no effect on the open chromatin configuration of this gene, as monitored by DNase I hypersensitivity, TSA selectively destabilized and enhanced the decay of the mature Her-2/neu transcripts (Scott et al., 2002) . In comparing the level of mRNA or protein of DNMT1 with loss of Pol II on the transcription initiation site, we show that while apicidin treatment almost completely depletes the mRNA and protein, about 60% of Pol II recruited on the promoter is dissociated, which is well correlated with previous observations showing that mutation in the E2F sites leads to a 65% loss of DNMT1 promoter activity (McCabe et al., 2005) . The effect of apicidin on the dissociation of Pol II from the transcription initiation site does not completely account for changes in the levels of mRNA and protein. Therefore, we tested the possibility that apicidin partially affects the mRNA stability, and found that DNMT1 mRNA levels show minimal changes in HeLa cells in the presence of apicidin (data not shown).
A previous study has shown that the murine Dnmt1 gene contains two important cis-elements within the core promoter region (Kimura et al., 2003) . One is an E2F binding site, and the other is a binding site for an unknown factor. Furthermore, transcription of DNMT1 is regulated in a complex fashion by E2F and other transcription factors through E2F-pRB-HDACdependent and -independent pathways. Recently, the transcriptional regulation of DNMT1 by the E2F-pRB pathway has been further confirmed by analysis of the protein expression and promoter activity of DNMT1 in pRB þ / þ and pRB À/À prostate epithelial cell lines rescued by tissue recombination (McCabe et al., 2005) . The human DNMT1 gene also exhibits putative E2F binding sites that align with those found in the murine, and the site is required for E2F-mediated transcriptional activation of DNMT1. The human DNMT1, like the murine Dnmt1 homologue, is positively and negatively regulated by E2F and pRB, respectively (McCabe et al., 2005) . We provide the first indication that E2F and pRB is able to bind to DNMT1 promoter in vivo. Our results of the ChIP analyses clearly show that E2F but not pRB is constitutively bound to the DNMT1 promoter region containing the E2F binding site in HeLa cells that are abnormally expressing DNMT1, while pRB is recruited into the E2F binding site in the presence of apicidin. The transcriptional repression by pRB has been shown to be due to direct interaction with a chromatin-modifying enzyme HDAC (Brehm et al., 1998; Magnaghi-Jaulin et al., 1998) . Consistent with the observation, apicidininduced recruitment of pRB on the promoter region is accompanied by the replacement of P/CAF with HDAC1 on the E2F binding site. Among HATs and HDACs tested, only P/CAF and HDAC1 are involved in the process (data not shown). Apicidin treatment leads to local hypoacetylation of H3 and H4 associated with nucleosomes of the promoter region, even though the global acetylation of histones increases, indicating that pRB-dependent recruitment of HDAC1 on the promoter region might be responsible for the apicidin repression of DNMT1 expression through hypoacetylation of the histone H3 and H4. It has been hypothesized that histone modifications act alone, sequentially or in combination to moderate the code recognized by nonhistone protein complexes that regulate gene expression (Jenuwein and Allis, 2001; Zhang and Reinberg, 2001; Fischle et al., 2003) . In addition to local hypoacetylation of histone H3 and H4, apicidin reduces the level of active marker, trimethyl-H3-K4 and increases that of repressive markers, trimethyl-H3-K9 and -K27 in the promoter region. This finding indicates that alteration of histone modifications induced by apicidin might be responsible for the downregulation of DNMT1, and that there is cross talk between histone acetylation and methylation in the E2F binding site, which might regulate the transcription of DNMT1. We also do not rule out the possibility that change in acetylation of E2F might be involved in the transcriptional repression of DNMT1 by apicidin, because E2F is thought to be regulated by reversible acetylation (Martinez-Balbas et al., 2000) .
Apicidin-induced repression of DNMT1 mRNA expression seems to require de novo protein synthesis, because both apicidin-mediated declines in the mRNA levels of DNMT1 and the recruitment of pRB and HDAC1 into the E2F binding site in the DNMT1 promoter are reversed by cotreatment with CHX, a blocker of protein synthesis. Most cervical carcinoma cell lines, including HeLa cells are infected with human papilloma virus and express the E6 and E7 oncoproteins, which bind to and inhibit the p53 and pRB, respectively (Goodwin and DiMaio, 2000) . Recently, DNMT1 has been demonstrated to be transcriptionally activated by the human polyomavirus Bradykinin B large T antigen and adenovirus E1a through pRb/E2F pathway (McCabe et al., 2006b) . Thus, the apicidin effect could be related to interfering with the function of viral oncoproteins. The protein de novo synthesized by apicidin might disrupt the interaction pRB with E7, thereby dissociating pRB from pRB-E7 complex, which can be recruited along with HDAC1 on the E2F binding site. Alternatively, the protein might increase free pRB protein through inhibition of the expression of E7 protein. Although a specific protein required for the recruitment of pRB and HDAC1 on the E2F binding site is not elucidated in this study, the identification of the protein would be of great of interest.
Abnormal overexpression of DNMT1 in HeLa cells might contribute to the cellular transformation. Indeed, specific downregulation of DNMT1 with siRNA leads to apoptosis of HeLa cells. However, apicidin does not induce the apoptotic cell death of HeLa cells (Kim et al., 2006) , although expression of DNMT1 in HeLa cells is downregulated by apicidin. These discrepancies might be due to the ability of cells to alter expression pattern of various genes involved in growth control or apoptosis through the modifications of chromatin structure by apicidin. As shown in our previous report (Kim et al., 2006) , apicidin gains the apoptotic potential in HeLa cells, only when apicidin-induced activation of nuclear factor-kB, a survival factor, is downregulated, indicating that the apoptotic potential of apicidin in HeLa cells could be mediated by downregulation of DNMT1. Therefore, DNMT1 overexpressed in HeLa cells could be a target for therapeutics of human cervix cancer.
Collectively, the findings support the hypothesis that apicidin downregulates DNMT1 expression through inducing repressive histone modifications via the recruitment of pRB and HDAC1 into the E2F binding site, which require a newly synthesized protein. The findings provide a new insight into molecular mechanisms by which the HDAC inhibitor apicidin represses the expression of DNMT1 and suggest a mechanistic rationale for the use of HDAC inhibitors in cancer therapeutics.
Materials and methods
Cell culture
The HeLa cell line, derived from human cervix cancer, was cultured in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (HyClone Laboratories, Logan, UT, USA) and 1% penicillin/streptomycin (Gibco). 
Reagents and antibodies
, a known antiprotozoal agent, was prepared from Fusarium sp. strain KCTC 16677 according to the method described previously (Park et al., 1999 
Western blot analysis
Cell lysates were boiled in Laemmli sample buffer for 3 min, and then 30 mg of each protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to polyvinylidene difluoride membranes; the membranes were blocked for 30 min in Tris-buffered saline (TBS) containing 0.1% Tween 20 and 5% (w/v) dry skim milk powder and incubated overnight with primary antibodies. The membranes were then washed with TBS-0.1% Tween 20, incubated for 1 h with a secondary antibody and visualized with an enhanced chemiluminescence detection kit (Amersham Life Sciences, Arlington Heights, IL, USA).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed using the Acetyl-Histone H3 Immunoprecipitation Assay Kit (Upstate Biotechnology, Charlottesville, VA, USA), according to the manufacturer's instructions. Chromatin from 1 Â 10 6 HeLa cells sheared by a sonicator was precleared with salmon sperm DNA-saturated protein G sepharose and then precipitated by acetylated histone H3 antibody and others. After Cell cycle assay Cell cycle assays were performed using Cycletest Plus DNA Reagent Kit (BD Biosciences, San Diego, CA, USA), according to the manufacturer's instructions. The profiles of cells in the cell cycle were analysed with a FACScan flow cytometer (BD Biosciences).
Stealth RNAi
Stealth RNAi duplex (Invitrogen Corporation, Carlsbad, CA, USA) was designed to DNMT1. HeLa cells were transfected with 20 nM control siRNA or 20 nM DNMT1 stealth RNAi using Lipofectamine 2000 (Invitrogen Corporation).
Apoptosis analysis assays
After treatment of cells with DNMT1 siRNA and control siRNA, cells were harvested, and the extent of apoptosis was determined by flow cytometric analysis using Annexin-V-FITC apoptosis detection kit (BD Biosciences). Cleavages of caspase-3 and PARP were determined by immunoblot analysis using antibodies against cleaved caspase-3 and cleaved PARP.
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